Ovarian cancer mutational processes drive site-specific immune evasion

Ignacio Vázquez-García, Florian Uhlitz, Nicholas Ceglia, Jamie L P Lim, Michelle Wu, Neeman Mohibullah, Juliana Niyazov, Arvin Eric B Ruiz, Kevin M Boehm, Viktoria Bojilova, Christopher J Fong, Tyler Funnell

Read Ovarian cancer mutational processes drive site-specific immune evasion by Ignacio Vázquez-García, Florian Uhlitz, Nicholas Ceglia, Jamie L P Lim, Michelle Wu, Neeman Mohibullah, Juliana Niyazov, Arvin Eric B Ruiz, Kevin M Boehm, Viktoria Bojilova, Christopher J Fong, Tyler Funnell in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9771812.txt.

Introduction

Vázquez-García and co-authors show how mutation patterns in ovarian cancer drive site-specific immune escape. High-grade serous ovarian cancer is a model of genome chaos. Its tumors spread through the belly in many foci. Immune therapy has worked poorly against this cancer so far.

The team studied 160 tumor sites from 42 untreated patients. Genome, single-cell, image, and protein assays were combined. Tumors with repair gene faults showed hot immune signaling. They were being edited by immune attack over time. Their T cells looked worn and over matured. Another mutation class showed the opposite immune picture. Those tumors excluded immune cells from their core zones. Calming TGF-beta signals ran high in that group. Immune states also differed by body site of the tumor. The authors tie treatment plans to both pattern and site.

Catalog record

CREATORIgnacio Vázquez-García, Florian Uhlitz, Nicholas Ceglia, Jamie L P Lim, Michelle Wu, Neeman Mohibullah, Juliana Niyazov, Arvin Eric B Ruiz, Kevin M Boehm, Viktoria Bojilova, Christopher J Fong, Tyler Funnell
COLLECTIONPAPERS
FORMATTXT
FILE SIZE115 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9771812

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Ovarian cancer mutational processes drive site-specific immune evasion By Ignacio Vázquez-García, Florian Uhlitz, Nicholas Ceglia, Jamie L P Lim, Michelle Wu, Neeman Mohibullah, Juliana Niyazov, Arvin Eric B Ruiz, Kevin M Boehm, Viktoria Bojilova, Christopher J Fong, Tyler Funnell Published in: Nature DOI: 10.1038/s41586-022-05496-1 ABSTRACT Abstract High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability1–4 patterned by distinct mutational processes5,6, tumour heterogeneity7–9 and intraperitoneal spread7,8,10. Immunotherapies have had limited efficacy in HGSOC11–13, highlighting an unmet need to assess how mutational processes and the anatomical sites of tumour foci determine the immunological states of the tumour microenvironment. Here we carried out an integrative analysis of whole-genome sequencing, single-cell RNA sequencing, digital histopathology and multiplexed immunofluorescence of 160 tumour sites from 42 treatment-naive patients with HGSOC. Homologous recombination-deficient HRD-Dup (BRCA1 mutant-like) and HRD-Del (BRCA2 mutant-like) tumours harboured inflammatory signalling and ongoing immunoediting, reflected in loss of HLA diversity and tumour infiltration with highly differentiated dysfunctional CD8+ T cells. By contrast, foldback-inversion-bearing tumours exhibited elevated immunosuppressive TGFβ signalling and immune exclusion, with predominantly naive/stem-like and memory T cells. Phenotypic state associations were specific to anatomical sites, highlighting compositional, topological and functional differences between adnexal tumours and distal peritoneal foci. Our findings implicate anatomical sites and mutational processes as determinants of evolutionary phenotypic divergence and immune resistance mechanisms in HGSOC. Our study provides a multi-omic cellular phenotype data substrate from which to develop and interpret future personalized immunotherapeutic approaches and early detection research. Subject terms: Cancer microenvironment, Cancer genomics, Genomic instability MAIN The principal defining features of high-grade serous ovarian cancer (HGSOC) are profound structural variations in the form of copy number alterations and genomic rearrangements, which accrue on a genetic background of nearly ubiquitous TP53 mutation14. Somatic and germline alterations in homologous recombination (HR) repair pathway genes such as BRCA1 and BRCA2 lead to HR deficiency (HRD) in approximately half of HGSOC cases15. Beyond gene alterations, patients stratify by endogenous mutational processes3,16 as inferred from structural variation patterns in whole-genome sequencing (WGS), including HRD subtypes (BRCA1-associated tandem duplications, HRD-Dup; BRCA2-associated interstitial deletions, HRD-Del), CCNE1 amplification-associated foldback inversion (FBI)-bearing tumours and CDK12-associated tandem duplicator (TD)-bearing tumours5,6. HGSOC presents a distinctive clinical challenge resulting from the widespread intraperitoneal disease at diagnosis. Long latency allows for broad periods of clonal diversification and tumour–immune interactions to unfold in the heterogeneous microenvironments of the peritoneal cavity7,10,17. This raises key questions about how underlying mutational processes and local tissue sites influence clonal selection, tumour microenvironments (TMEs) and immune recognition. We carried out a prospective study, capturing mutational processes from WGS, cell phenotypes from single-cell RNA sequencing (scRNA-seq) and spatial topology from in situ multiplexed cellular imaging in multi-site cases of HGSOC. Our findings identify distinct immunostimulatory and immunosuppressive mechanisms that co-segregate with sites of disease and mutational processes, thereby defining new determinants of immune recognition and escape in HGSOC. Multi-site tissue biopsies (n = 160) were collected from newly diagnosed, treatment-naive patients (n = 42) undergoing laparoscopy or primary debulking surgeries over a 24-month period (Fig. 1a). Collection took place at anatomical sites including adnexa (that is, potential primary lesions), omentum, peritoneum, bowel, ascites and other intraperitoneal sites (Extended Data Fig. 1a). The clinical characteristics of all patients are summarized in Extended Data Fig. 1b and Supplementary Table 1. Patient samples were profiled using scRNA-seq on CD45+ and CD45− flow-sorted fractions (Supplementary Table 2), haematoxylin and eosin (H&E) staining and multiplexed immunofluorescence (mpIF) on fixed tissue sections, clinical tumour–normal sequencing of 468 cancer genes by MSK-IMPACT and whole-genome tumour–normal sequencing (Extended Data Fig. 1a,b and Methods). WGS copy number profiles were highly concordant with an external ‘meta-cohort’ derived from several HGSOC WGS studies5 (Extended Data Fig. 2a). Mutational signature inference from WGS data yielded 16 HRD-Dup, 6 HRD-Del and 14 FBI tumours (Extended Data Figs. 1b and 2b,c and Supplementary Tables 1 and 3), with model features consistent with previous reports5 (Extended Data Fig. 2d,e), stable across multiple computational methods18,19 and in agreement with BRCA1 and BRCA2 mutations and clinical HRD testing (Extended Data Fig. 2b). Furthermore, tumours with high-level amplifications in CCNE1 (Extended Data Fig. 2f) and MYC exhibited expected distributions of gene amplifications within signature assignments and cis-acting gene expression correlates (Extended Data Fig. 2g,h). [Figure: TME of HGSOC at single-cell resolution.a, Overview of the MSK SPECTRUM cohort and specimen collection workflow. b, UMAP plot of cells profiled by scRNA-seq coloured by patient. Cell types are highlighted with grey outlines. c, Patient specificity for each cell type (Methods). Ov, ovarian. d, Number of cells identified per cell type next to a UMAP plot with cells coloured by cell type. e, Number of cells profiled per tumour site next to a UMAP plot with cells coloured by tumour site. UQ, upper quadrant. f, Site-specific enrichment of cell type composition in scRNA-seq, H&E and mpIF data fitted using a GLM. GLMs for H&E and mpIF data were separated by tumour (T) and stroma (S) regions. The colour gradient indicates the log2-transformed odds ratio (red, enrichment; blue, depletion), and sizes indicate the Bonferroni-corrected –log10(P value). g, Cell type composition based on scRNA-seq data for CD45− and CD45+ samples. Upper panels, absolute and relative cell type numbers; lower panels, box plot distributions of sample ranks with respect to tumour site. h, Cell type composition based on H&E with lymphocyte ranks in tumour and stroma. Panels are analogous to those in g. i, Cell type composition based on mpIF with CD8+ T cell ranks in tumour and stroma. Panels are analogous to those in g. For c and g–i, violin plots and box plots are shown as the median, top and bottom quartiles; whiskers correspond to 1.5× interquartile range (IQR). *P < 0.05, **P < 0.01.] [Figure: Multi-site, multi-modal profiling of malignant cells and the TME.a, Schematic of the MSK SPECTRUM specimen collection workflow including surgery, single-cell suspensions for scRNA-seq and biobanking of snap-frozen and FFPE samples. b, Cohort overview. Top panel, Oncoprint of selected somatic and germline mutations per patient and cohort-wide prevalence. Single nucleotide variants (SNVs), indels and fusions shown are detected by targeted panel sequencing (MSK-IMPACT). Focal amplifications and deletions are detected by whole-genome sequencing (WGS). Patient data include mutational signature subtype, patient age, staging following FIGO Ovarian Cancer Staging guidelines, and type of surgical procedure. Bottom panel, Sample and data inventory indicating number of co-registered multi-site datasets: single-cell RNA sequencing, H&E whole-slide images, multiplexed immunofluorescence, WGS and MSK-IMPACT.] [Figure: Inference of SNV and SV mutational signatures by WGS.a, Landscape of copy number gains and losses in the MSK SPECTRUM cohort (n = 40) and the HGSOC samples in the metacohort (n = 170). The fraction of tumour samples with gains or losses is shown on the y-axis, calculated in 500-kb genomic bins shown on the x-axis. b, First panel, Oncoprint of selected somatic and germline mutations per patient and cohort-wide prevalence by MSK-IMPACT. Patients are grouped by mutational signature. Second panel, heatmap of standardized probabilities for genomic features used to infer mutational signature subtypes from WGS using MMCTM. Features used for inference (in rows) are grouped into single nucleotide variant (SNV) and structural variation (SV) features. SV features include duplications (S-Dup, M-Dup, L-Dup), deletions (S-Del, L-Del), unclustered and clustered foldback inversions (FBI/Inv, Clust-FBI), clustered rearrangements

Read the complete text